Secondary Metabolites of Medicinal Plants. Bharat SinghЧитать онлайн книгу.
cannabinoid production was increased by the UV-B radiation treatment in the cells of C. sativa (Pate 1983). It is clear from findings that the genes of polyketide synthase catalyze the synthesis of olivetolic acid. This has strong similarity with chalcone synthase; it is considered as one of the important UV-B-regulated enzyme (Pacifico et al. 2008; Zhang and Björn 2009). Cannabidiol was synthesized from nonenzymatic decarboxylation of its precursor molecule, cannabidiolic acid. The cannabidiolic acid inhibits the growth of MDA-MB-231 human breast cancer cells. In this mechanism, the growth of these cancer cells was inhibited by cyclic adenosine monophosphate (AMP)-dependent protein kinase A, by clubbing of activated GTPase, Ras homolog gene family member A (RhoA). It was proposed that RhoA signaling pathway activation leads to the inhibition of the mobility of MDA-MB-231 cancer cells (Takeda et al. 2012). Cannabidiol was the most effective in the analgesic activity tested orally and was used topically to antagonize tetradecanoylphorbol acetate-induced erythema of skin. Actually, Δ1-tetrahydrocannabinol and cannabinol were not more effective in analgesic activity; it suggests a structural relationship between analgesic activity and anti-inflammatory activity among the cannabinoids related to their peripheral actions and separate from the central effects of Δ1-tetrahydrocannabinol (Formukong et al. 1988).
References
1 Ahmed, S.A., Ross, S.A., Slade, D. et al. (2008). Cannabinoid ester constituents from high-potency Cannabis sativa. J. Nat. Prod. 71: 536–542.
2 Ahmed, S.A., Ross, S.A., Slade, D. et al. (2015). Minor oxygenated cannabinoids from high potency Cannabis sativa L. Phytochemistry 117: 194–199.
3 Aizpurua-Olaizola, O., Omar, J., Navarro, P. et al. (2014). Identification and quantification of cannabinoids in Cannabis sativa L. plants by high performance liquid chromatography-mass spectrometry. Anal. Bioanal. Chem. 406: 7549–7560.
4 Borgelt, L.M., Franson, K.L., Nussbaum, A.M., and Wang, G.S. (2013). The pharmacologic and clinical effects of medical Cannabis. Pharmacotherapy 33: 195–209.
5 Braemer, R. and Paris, M. (1987). Biotransformation of cannabinoids by a cell suspension culture of Cannabis sativa L. Plant Cell Rep. 6: 150–152.
6 Brotchie, J.M. (2003). CB1 cannabinoid receptor signalling in Parkinson's disease. Curr. Opin. Pharmacol. 3: 54–61.
7 Choi, Y.H., Kim, H.K., Hazekamp, A. et al. (2004). Metabolomic differentiation of Cannabis sativa cultivars using 1H NMR spectroscopy and principal component analysis. J. Nat. Prod. 67: 953–957.
8 ElSohly, M.A. and Slade, D. (2005). Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 78: 539–548.
9 ElSohly, M.A., El-Feraly, F.S., and Turner, C.E. (1977). Isolation and characterization of (+)-cannabitriol and (−)-10-ethoxy-9-hydroxy-D6a(10a)-tetrahydrocannabinol: two new cannabinoids from Cannabis sativa L. extract. Lloydia 40 (3): 275–280.
10 ElSohly, H.N., Boeren, E.G., Turner, C.E., and ElSohly, M.A. (1984). Constituents of Cannabis sativa L. XXIIII: cannabitetrol, a new polyhydroxylated cannabinoid. In: The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects (eds. S. Agurell, W.L. Dewey and R.E. Willette), 89–96. New York: Academic Press.
11 Elzinga, S., Fischedick, J., Podkolinski, R., and Raber, J.C. (2015). Cannabinoids and terpenes as chemotaxonomic markers in Cannabis. Nat. Prod. Chem. Res. 3: 181.
12 Fellermeier, M., Eisenreich, W., Bacher, A., and Zenk, M.H. (2001). Biosynthesis of cannabinoids: incorporation experiments with 13C-labeled glucoses. Eur. J. Biochem. 268: 1596–1604.
13 Fischedick, J., Van Der Kooy, F., and Verpoorte, R. (2010a). Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor. Chem. Pharm. Bull. 58: 201–207.
14 Fischedick, J.T., Hazekamp, A., Erkelens, T. et al. (2010b). Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes. Phytochemistry 71: 2058–2073.
15 Flores-Sanchez, I.J. and Verpoorte, R. (2008). Secondary metabolism in Cannabis. Phytochem. Rev. 7: 615–639.
16 Flores-Sanchez, I.J., Pčc, J., Fei, J. et al. (2009). Elicitation studies in cell suspension cultures of Cannabis sativa L. J. Biotechnol. 143: 157–168.
17 Formukong, E.A., Evans, A.T., and Evans, F.J. (1988). Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation 12: 361–371.
18 Galal, A.M., Slade, D., Gul, W. et al. (2009). Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. Recent Pat. CNS Drug Discov. 4: 112–136.
19 Giacoppo, S., Mandolino, G., Galuppo, M. et al. (2014). Cannabinoids: new promising agents in the treatment of neurological diseases. Molecules 19: 18781–18816.
20 Grote, H. and Spiteller, G. (1978a). New cannabinoids II. J. Chromatogr. 154: 13–23.
21 Grote, H. and Spiteller, G. (1978b). New cannabinoids. The structure of cannabicoumaronone and analogous compounds. Tetrahedron 34: 3207–3213.
22 Gubellini, P., Picconi, B., Bari, M. et al. (2002). Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 22: 6900–6907.
23 Hampson, A.J., Grimaldi, M., Axelrod, J., and Wink, D. (1998). Cannabidiol and (−)D9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U.S.A. 95: 8268–8273.
24 Hanuš, L.O., Meyer, S.M., Muňoz, E. et al. (2016). Phytocannabinoids: a unified critical inventory. Nat. Prod. Rep. 33: 1357–1392.
25 Happyana, N., Agnolet, S., Muntendam, R. et al. (2013). Analysis of cannabinoids in laser-microdissected trichomes of medicinal Cannabis sativa using LCMS and cryogenic NMR. Phytochemistry 87: 51–59.
26 Hartsel, S.C., Loh, W.H.T., and Robertson, L.W. (1983). Biotransformation of cannabidiol to cannabielsoin by suspension cultures of Cannabis sativa and Saccharum officinarum. Planta Med. 48: 17–19.
27 Hillig, K.W. (2004). A chemotaxonomic analysis of terpenoid variation in Cannabis. Biochem. Syst. Ecol. 32: 875–891.
28 Jiang, H.-E., Li, X., Zhao, Y.-X. et al. (2006). A new insight into Cannabis sativa (Cannabaceae) utilization from 2500-year-old Yanghai Tombs, Xinjiang, China. J. Ethnopharmacol. 108: 414–422.
29 Johnson, K.A., Conn, P.J., and Niswender, C.M. (2009). Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol. Disord. Drug Targets 8: 475–491.
30 Kajima, M. and Piraux, M. (1982). The biogenesis of cannabinoids in Cannabis sativa. Phytochemistry 21: 67–69.
31 Lewis, M.M., Yang, Y., Wasilewski, E. et al. (2017). Chemical profiling of medical Cannabis extracts. ACS Omega 2: 6091–6103.
32 Li, H.-L. (1973). The origin and use of Cannabis in Eastern Asia: linguistic-cultural implications. Econ. Bot. 28: 293–301.
33 Mackie, K., Devane, W.A., and Hille, B. (1993). Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44: 498–503.
34 Mahlberg, G. and Kim, E.S. (2004). Accumulation of cannabinoids in glandular trichomes of Cannabis (Cannabaceae). J. Ind. Hemp 9: 15–36.
35 Manduca, A., Campolongo, P., and Trezza, V. (2012). Cannabinoid modulation of mother-infant interaction: is it just about milk? Rev. Neurosci. 23: 707–722.
36 Morimoto, S., Komatsu, K., Taura, F., and Shoyama, Y. (1998). Purification and characterization of cannabichromenic acid synthase from Cannabis sativa. Phytochemistry 49: 1525–1529.
37 Morimoto, S., Tanaka, Y., Sasaki, K. et al. (2007). Identification and characterization of cannabinoids that induce cell death through mitochondrial permeability transition in Cannabis leaf cells. J. Biol. Chem. 282: 20739–20751.
38 Nascimento, I.R., Costa, H.B., Souza, L.M. et al. (2015). Chemical identification of cannabinoids in street marijuana samples using electrospray ionization FT-ICR mass spectrometry. Anal. Methods